[C:1]([C@@H:3]1[CH2:7][CH2:6][CH2:5][N:4]1[C:8](=[O:30])[CH2:9][N:10]([CH2:18][C:19]([N:21]1[CH2:29][C:28]2[C:23](=[CH:24][CH:25]=[CH:26][CH:27]=2)[CH2:22]1)=[O:20])C(=O)OC(C)(C)C)#[N:2].Cl.O1CCOCC1.CCOCC>O1CCOCC1>[CH2:22]1[C:23]2[C:28](=[CH:27][CH:26]=[CH:25][CH:24]=2)[CH2:29][N:21]1[C:19](=[O:20])[CH2:18][NH:10][CH2:9][C:8]([N:4]1[CH2:5][CH2:6][CH2:7][C@H:3]1[C:1]#[N:2])=[O:30]The t-butyl (S)-[2-(cyanopyrrolidin-1-yl)-2-oxoethyl]-[2-(1,3-dihydrois oindol-2-yl)-2-oxoethyl]carbamate (280 mg) obtained above was dissolved in 1,4-dioxane (1.0 ml), and 4 N Hydrochloric acid/1,4-dioxane (1.0 ml) was added thereto and stirred for 30 minutes with ice cooling. Ether was added thereto, and precipitated crystals were collected by filtration and dried under reduced pressure to give a hydrochloride (240 mg, Y.: quant.) of the title compound.